TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.

被引：2
|
作者：
Van Cutsem, Eric
Benedetti, Fabio M.
Mizuguchi, Hirokazu
Mayer, Robert J.
Falcone, Alfredo
Garcia-Carbonero, Rocio
Tabernero, Josep
Sobrero, Alberto F.
Peeters, Marc
Zaniboni, Alberto
Yoshino, Takayuki
Shimada, Yasuhiro
Yamazaki, Kentaro
Komatsu, Yoshito
Hochster, Howard S.
Lenz, Heinz-Josef
Ben Tran
Ohtsu, Atsushi
机构：
[1] Univ Hosp Leuven, Leuven, Belgium
[2] Taiho Oncol Inc, Princeton, NJ USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Azienda Osped Univ Pisana, Pisa, Italy
[5] Hosp Univ Virgen del Rocio, Seville, Spain
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] IRCCS AOU San Martino IST, Genoa, Italy
[8] Univ Antwerp Hosp, Edegem, Belgium
[9] Fdn Poliambulanza, Brescia, Italy
[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[11] Natl Canc Ctr, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo, Japan
[12] Saitama Canc Ctr, Saitama, Japan
[13] Hokkaido Univ, Hosp Canc Ctr, Sapporo, Hokkaido, Japan
[14] Yale Canc Ctr, New Haven, CT USA
[15] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[16] Royal Melbourne Hosp, Melbourne, Vic, Australia
[17] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.638
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
638
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial
    F. Longo-Muñoz
    G. Argiles
    J. Tabernero
    A. Cervantes
    C. Gravalos
    C. Pericay
    S. Gil-Calle
    H. Mizuguchi
    A. Carrato-Mena
    M. L. Limón
    R. Garcia-Carbonero
    Clinical and Translational Oncology, 2017, 19 : 227 - 235
  • [22] Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial
    Longo-Munoz, F.
    Argiles, G.
    Tabernero, J.
    Cervantes, A.
    Gravalos, C.
    Pericay, C.
    Gil-Calle, S.
    Mizuguchi, H.
    Carrato-Mena, A.
    Limon, M. L.
    Garcia-Carbonero, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (02): : 227 - 235
  • [23] A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)
    Lee, V.
    Zahurak, M.
    Cercek, A.
    Verheul, H.
    Lenz, H.
    Jones, P.
    Baylin, S.
    Parkinson, R.
    Rami, V.
    Lilly, E.
    Miles, T.
    Brown, T.
    Ahuja, N.
    El Khoueiry, A.
    Azad, N.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S12 - S12
  • [24] TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial
    Karthaus, M.
    Van Cutsem, E.
    Mayer, R. J.
    Ohtsu, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 197 - 198
  • [25] The relevance of thymidine kinase 1 (TK1) expression to treatment efficacy of TAS-102 and prognosis in patients (pts) with metastatic colorectal cancer (mCRC)
    Komatsu, Y.
    Yoshino, T.
    Mizunuma, N.
    Yamazaki, K.
    Nishina, T.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S548 - S548
  • [26] APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Kuboki, Yasutoshi
    Yoshino, Takayuki
    Kato, Takeshi
    Kagawa, Yoshinori
    Gamoh, Makio
    Yasui, Hirofumi
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Satake, Hironaga
    Goto, Masahiro
    Tanioka, Hiroaki
    Oki, Eiji
    Kotaka, Masahito
    Makiyama, Akitaka
    Denda, Tadamichi
    Soeda, Junpei
    Shibuya, Kazunori
    Iwata, Masaru
    Oba, Koji
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients.
    Zheng, Hanke
    Yu, Tianzhou
    Romley, John
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Effect of regorafenib and TAS-102 in metastatic colorectal cancer (mCRC) patients on survival in salvage line with different toxicity profile.
    Sugimoto, Naotoshi
    Yoshinami, Tetsuhiro
    Yamamoto, Sachiko
    Yagi, Toshinari
    Imamura, Fumio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] A first combination phase I study of TAS-102 and irinotecan (hi) in Japanese patients (pts) with metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine (FU) and oxaliplatin (Ox)
    Yamazaki, K.
    Doi, T.
    Yoshino, T.
    Fuse, N.
    Boku, N.
    Koizumi, W.
    Shimada, K.
    Takinishi, Y.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S555 - S555
  • [30] EFFECT OF BEVACIZUMAB IN PATIENTS OVER 65 YEARS OF AGE WITH METASTATIC COLORECTAL CANCER (MCRC)
    Cassidy, J.
    Giantonio, B.
    Kabbinavar, F.
    Hurwitz, H.
    Rohr, U. P.
    Saltz, L. B.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
12345